Even with better economic data, the market is betting the Fed will cut rates by 50 basis points in July, after dovish comments from two Fed officials.Market Insiderread more
Iran on Friday denied President Donald Trump's assertion that the U.S. Navy has destroyed one of its drones, saying all of its unmanned planes were safe.Politicsread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Boeing will take a nearly $5 billion charge in the second quarter to compensate 737 Max customers as the planes remain grounded.Airlinesread more
Earlier, Williams delivered a speech at the annual meeting of the Central Bank Research Association in which he said, "It's better to take preventative measures than to wait...The Fedread more
Market researcher James Bianco believes it's crucial to get a half point cut at the next Federal Reserve meeting.Trading Nationread more
The base version of the sports car will punch out 495 horsepower, 40 more than the seventh-generation car and enough to launch it from 0 to 60 in "less than three seconds"...Autosread more
President Trump said he's looking at the JEDI contract that will be awarded to Microsoft or Amazon.Technologyread more
Taiwanese President Tsai Ing-wen is expected to stop over in the U.S. on Friday on her way back from visiting diplomatic allies in the Caribbean, a move that's sure to make...China Politicsread more
Animation fans and Kyoto residents gathered at the site of Japan's worst mass killing in 18 years on Friday, offering flowers and prayers for the 33 people who died in an...Asia Newsread more
Libra and bitcoin are different in a lot of ways, from the technology behind them to the way they're used.Technologyread more
Shares of drugmakers Mylan, which was also named in the lawsuit, were trading 10% lower in afternoon trading.
The states, led Connecticut Attorney General William Tong, claim 20 drug companies, including Teva USA, "systematically" divided up the market for generic drugs to avoid competing with one another, according to a 500-page lawsuit filed late Friday in the U.S. District Court in Connecticut. In some cases, pharmaceutical executives conspired to either prevent prices from dropping or raise them, the lawsuit claimed.
"This is an organized effort to conspire and fix prices — a highly illegal violation of antitrust laws," Tong said.
The lawsuit comes as President Donald Trump and Congress attempt to bring down high prescription drug prices, which accounted for roughly 12% of total health-care spending in the U.S. in 2016. Just last week, the Trump administration announced it would required pharmaceutical companies to disclose the list price of their prescription medicines in television commercials in an effort to "shame" them into lowering consumer costs.
In response to the lawsuit, a spokesperson for Teva said "the allegations in this new complaint, and in the litigation more generally, are just that – allegations."
"Teva continues to review the issue internally and has not engaged in any conduct that would lead to civil or criminal liability," the spokesperson said. "Teva delivers high-quality medicines to patients around the world, and is committed to complying with all applicable laws and regulations in doing so."
The generic drug industry was created by Congress in 1984 in an effort to bring down drug prices by allowing companies to make their own identical version of a drug once a brand-name drug's patent expired.
Israel-based Teva is the world's largest generic drugmaker.
For more on investing in health-care innovation, click here to join CNBC at our Healthy Returns Summit in New York City on May 21.